tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

TRDA Stock Latest News

Advancing Exon-Skipping and Undervalued DM1 Collaboration Underscore Buy Rating on Entrada Therapeutics
RatingsAdvancing Exon-Skipping and Undervalued DM1 Collaboration Underscore Buy Rating on Entrada Therapeutics
19d ago
TRDA
Entrada Therapeutics price target raised to $19 from $13 at Roth Capital
PremiumThe Fly
Entrada Therapeutics price target raised to $19 from $13 at Roth Capital
22d ago
TRDA
Entrada Therapeutics reports Q4 EPS (94c), consensus ($1.24)
PremiumThe Fly
Entrada Therapeutics reports Q4 EPS (94c), consensus ($1.24)
23d ago
TRDA
Advancing DMD and DM1 Pipeline Positions Entrada for Multiple Near‑Term Catalysts and Upside Potential
PremiumRatings
Advancing DMD and DM1 Pipeline Positions Entrada for Multiple Near‑Term Catalysts and Upside Potential
1M ago
TRDA
Entrada Therapeutics: Advancing ENTR-601-44 Positions Platform for Best-in-Class Dystrophin Restoration and Attractive Risk/Reward
PremiumRatings
Entrada Therapeutics: Advancing ENTR-601-44 Positions Platform for Best-in-Class Dystrophin Restoration and Attractive Risk/Reward
1M ago
TRDA
Entrada announces DMC recommends initiation of Cohort 2 in ELEVATE-44-201 study
PremiumThe FlyEntrada announces DMC recommends initiation of Cohort 2 in ELEVATE-44-201 study
1M ago
TRDA
Entrada Therapeutics initiated with a Buy at Guggenheim
Premium
The Fly
Entrada Therapeutics initiated with a Buy at Guggenheim
1M ago
TRDA
Entrada Therapeutics initiated with a Buy at Guggenheim
Premium
The Fly
Entrada Therapeutics initiated with a Buy at Guggenheim
1M ago
TRDA
Entrada Therapeutics initiated with an Outperform at Oppenheimer
PremiumThe Fly
Entrada Therapeutics initiated with an Outperform at Oppenheimer
2M ago
TRDA
Entrada Therapeutics: Advancing DMD and DM1 Pipeline with Emerging Ophthalmology Assets Supports Buy Rating and $20 Target
PremiumRatings
Entrada Therapeutics: Advancing DMD and DM1 Pipeline with Emerging Ophthalmology Assets Supports Buy Rating and $20 Target
2M ago
TRDA
Entrada Therapeutics highlights RNA pipeline progress and outlook
PremiumCompany Announcements
Entrada Therapeutics highlights RNA pipeline progress and outlook
2M ago
8K
TRDA
Entrada Therapeutics reports progress across development portfolio
PremiumThe Fly
Entrada Therapeutics reports progress across development portfolio
2M ago
TRDA
Entrada Therapeutics Reports Increased Losses Amid R&D Expansion
PremiumCompany AnnouncementsEntrada Therapeutics Reports Increased Losses Amid R&D Expansion
4M ago
TRDA
Entrada Therapeutics price target lowered to $13 from $17 at Roth Capital
Premium
The Fly
Entrada Therapeutics price target lowered to $13 from $17 at Roth Capital
4M ago
TRDA
Promising Outlook for Entrada Therapeutics: Strategic Advancements in DMD and DM1 with Novel EEV Platform
Premium
Ratings
Promising Outlook for Entrada Therapeutics: Strategic Advancements in DMD and DM1 with Novel EEV Platform
4M ago
TRDA
Promising Advancements and Strategic Positioning Drive Buy Rating for Entrada Therapeutics Inc.
PremiumRatings
Promising Advancements and Strategic Positioning Drive Buy Rating for Entrada Therapeutics Inc.
4M ago
TRDA
Entrada Therapeutics files $400M mixed securities shelf
PremiumThe Fly
Entrada Therapeutics files $400M mixed securities shelf
5M ago
TRDA
Entrada Therapeutics reports Q3 EPS ($1.06), consensus (96c)
PremiumThe Fly
Entrada Therapeutics reports Q3 EPS ($1.06), consensus (96c)
5M ago
TRDA
Entrada Therapeutics: Undervalued Leader in RNA Therapeutics with Promising DMD Pipeline
PremiumRatings
Entrada Therapeutics: Undervalued Leader in RNA Therapeutics with Promising DMD Pipeline
5M ago
TRDA
3 Best Stocks to Buy Now, 10/24/2025, According to Top Analysts
PremiumMarket News3 Best Stocks to Buy Now, 10/24/2025, According to Top Analysts
5M ago
EXOD
NRIX
Entrada Therapeutics initiated with Early-Stage Biotech at Goldman Sachs
Premium
The Fly
Entrada Therapeutics initiated with Early-Stage Biotech at Goldman Sachs
6M ago
TRDA
Entrada Therapeutics price target lowered to $17 from $21 at Roth Capital
Premium
The Fly
Entrada Therapeutics price target lowered to $17 from $21 at Roth Capital
8M ago
TRDA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >